---
schema_version: "secwatch.filing_event.v1"
accession: "0001013762-23-002900"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2023-10-10T23:59:59+00:00"
generated_at: "2026-06-10T02:18:31.692149+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "low"
source: SEC EDGAR
---

# Relmada Therapeutics updates corporate presentation on CNS pipeline

## Summary
- Filed corporate presentation dated October 10, 2023 as Exhibit 99.1.
- No specific financial or clinical data disclosed in the 8-K filing.
- Presentation title: 'Targeting Major Advances in the Treatment of CNS Disorders'.

## SEC filing metadata
- accession: 0001013762-23-002900
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2023-10-10T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000101376223002900/0001013762-23-002900-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000101376223002900/ea186591-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001013762-23-002900
- JSON: https://secwatch.observer/filing/0001013762-23-002900.json
- Plain text: https://secwatch.observer/filing/0001013762-23-002900.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.